BACKGROUND It remains unknown how the introduction of high-sensitivity cardiac troponin T (hs-cTnT) has
which have been increasingly used in clinical practice for some years, allow more rapid rule-in and rule-out of MI compared with cTn assays (3) (4) (5) .
Nevertheless, it has been suggested that implementation of hs-cTn assays could diminish the clinical specificity for MI diagnosis and potentially lead to increased use of resources. However, in cohort studies of patients with chest pain in the emergency department, the introduction of hs-cTn assays has been associated with small or no increases in coronary angiographies and revascularizations, and a sharp decline in admission rates for chest pain (6) (7) (8) (9) .
In patients admitted to coronary care units, the 1-year mortality rate was unchanged after the introduction of the high-sensitivity cardiac troponin T (hs-cTnT) assay (10) . To the best of our knowledge, no large cohort study has investigated the impact of the introduction of hs-cTn assays on the risk of mortality, reinfarctions, and resource use in unselected MI patients. Therefore, we conducted a nationwide study comprising patients with MI during the years when the hs-cTnT assay was adopted widely in Sweden.
METHODS STUDY POPULATION.
We included all patients who were hospitalized for a first MI during the period from 2009 to 2013 in Sweden and were diagnosed using either cTn or hs-cTnT at hospitals where the 99th percentile value was used as the decision limit for MI.
DATA SOURCES. We used the Swedish National Patient Registry, which includes all hospitalizations in Sweden, to retrieve the study population, their characteristics, and outcomes. We then added information about medication from the Prescribed Drug Registry, and deaths from the Cause-of-Death Registry. Information on cTn assays; and the locally applied cutoffs for the diagnosis of MI were obtained from the SWEDEHEART registry (the Swedish Webbased system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies), from local representatives of all hospitals, and by online search using the Internet. The registries and the construction of the database are described in detail in the Online Appendix.
TROPONIN ASSAYS. From 2009 to 2012, the current iteration of the hs-cTnT assay (Roche Diagnostics, Basel, Switzerland) was the only higher-precision method used in Sweden. For this assay, the lowest concentration measurable with a 10% coefficient of variation is 13 ng/l, the limit of detection is 5 ng/l and the 99th percentile value among healthy controls is 14 ng/l (11). However, some hospitals in Sweden initially used higher diagnostic cutoffs, in the range of 30 to 40 ng/l, for MI (Online Table 1 ).
DEFINITIONS. The index date was defined as the date when the patient was hospitalized for MI. Medication at baseline was defined as a minimum of 2 dispensed prescriptions during the 365 days preceding the index date. Medication at discharge was defined as at least 1 dispensed prescription during the 6 months following the index date. International Classification of Disease-9th and 10th Revisions were used to retrieve information about comorbidities (Online Table 2 ). Diabetes at baseline was defined as ongoing medication with any hypoglycemic agent. In multivariable models, the diabetes definition was extended to include patients who, in addition, had any hypoglycemic agent dispensed 6 months following the index date. The Anatomical Therapeutic Chemical classification codes for medication are listed in Online Table 3 . OUTCOMES. The primary outcome was all-cause mortality. Secondary outcomes were: 1) reinfarction;
2) coronary angiography; and 3) coronary revascularization. In the outcomes analyses, we excluded 9,747 patients who were diagnosed with MI at hospitals that used the hs-cTnT assay with a higher decision limit for MI than the 99th percentile value (Online Table 1 Number of myocardial infarctions, and relative risks with 95% confidence intervals of being diagnosed with myocardial infarction in the 3 months following compared with the 3 months preceding the introduction of the high-sensitivity cardiac troponin T assay at each individual hospital in Sweden. cTn ¼ conventional cardiac troponin; hs-cTnT ¼ high-sensitivity cardiac troponin T; MI ¼ myocardial infarction; RR ¼ relative risk.
Odqvist et al. The proportional hazards assumption was met.
One-year absolute risk was calculated as the proportion of patients that came under risk and experienced the specific outcome within 1 year.
SAS software version 9.4 of the SAS System for MS Windows (SAS Institute, Cary, North Carolina) was used for all statistical calculations.
RESULTS
STUDY POPULATION. In total, we included 87,879 patients with a first MI, of whom 47,133 (54%)
were diagnosed using cTn and 40,746 (46%) were diagnosed using hs-cTnT ( Table 1) .
INTRODUCTION OF THE HS-cTnT ASSAY IN SWEDEN.
Only 4 of 71 (5.6%) hospitals in Sweden started using the hs-cTnT assay concurrently with the 99th percentile value as the decision limit for MI in 2009
(Central Illustration). Nine (13%) hospitals that introduced the hs-cTnT assay initially used a decision limit of 30 or 40 ng/l for the diagnosis of MI (Online Table 1 When we compared the 90 days that followed with the 90 days that preceded the introduction of the hscTnT assay at each hospital, we found a 5% increase were similar to those for MI patients ( Table 2) . For reasons of comparison, the numbers of MIs and unstable angina at hospitals that used the hs-cTnT assay with a higher decision limit or settings other than acute care hospitals are shown in Table 2 . Yearly event rates, 1-year absolute risks, and HRs for all-cause mortality from 2009 through 2013 are shown in Table 3 . Table 3 . Reinfarctions were diagnosed using the hs-cTnT assay in 17% of cases in the cTn group and in 81% of cases in the hs-cTnT group (Online Table 4 ). Values are n, mean AE SD, or n (%). *Includes MI and UA cases that were diagnosed in hospitals using the hs-cTnT assay, but with a decision limit for MI of 30 ng/l or 40 ng/l; or in nursing homes, or health care settings other than acute care hospitals. Incidence rate is calculated in relation to the Swedish population >20 years of age.
py ¼ person-years; UA ¼ unstable angina; other abbreviations as in Table 1 .
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found a 3% (95% CI: 0% to 9%), and 4% (95% CI:
0% to 11%) nonsignificant increase in coronary angiographies and revascularizations, respectively (Online Figures 2 and 3 ). There were no differences in medication at discharge between groups, except for statins, which were dispensed slightly more often to patients in the hs-cTnT group (Online Table 5 ). The hs-cTn assays were introduced in clinical practice in 2009, after studies found an improved rulein of MI and risk assessment in patients with chest pain (3, 4) . Later on, interest turned to the improved and faster rule-out of patients in the emergency department, where algorithms using a second troponin level, analyzed only 1 h after the admission troponin level, were found to be efficient (5, 17) .
DISCUSSION
Instead of increases in admission rates for chest pain, as had been feared, some studies found no changes in admissions in the short term (7), whereas others found sharp reductions over the first few years of use, (9) without any or with only small increases in coronary angiographies and revascularizations (6) (7) (8) (9) (10) 13, 14) .
In our study, which exclusively involved patients with MI, we found no change in mortality, but a reduced risk of reinfarctions in the hs-cTnT group.
Furthermore, there were no major differences in medication at discharge between groups. However, there was an increase in coronary angiographies and revascularizations in the hs-cTnT group, which may have been related to the reduced risk of reinfarction.
This increase in resource use is of potential concern, not only because it will lead to increased costs, but also because it will expose patients to risks of complications. Indeed, if this increase in coronary angiographies and revascularization were associated with an improved prognosis, the patient would benefit.
The magnitude of increase in coronary angiographies and revascularizations associated with the introduction of the hs-cTnT assay was similar to that found in a cohort of chest pain patients in a recently published single-center Swedish study (14) . When we compared STUDY LIMITATIONS. We had no information about whether or not patients were cared for in a coronary care unit, which may have affected, not only the length of hospital stay, but also the frequency of coronary angiographies and revascularizations.
As with every observational cohort study, we cannot rule out that there was residual confounding present. However, considering that patients tested with cTn had characteristics virtually identical to Full statistical model was adjusted for age, sex, chronic kidney disease, hospital, heart failure, prior stroke, COPD, diabetes, prior cardiac revascularization (percutaneous coronary intervention or coronary artery bypass grafts), and use of aspirin, P2Y12 inhibitor, beta-blockers, ACE/ARB, and statins the first 6 months following the index date.
Abbreviations as in Tables 1 and 3 .
Odqvist et al. However, as this was not paralleled by an increase in the incidence of unstable angina, the overall importance of potential misclassifications on the main results of our analysis appears to be limited.
Although differences in medication use after discharge were small, we did not have information about intensity of statin therapy, which may have been associated with the observed reduction in reinfarction.
CONCLUSIONS
In a nationwide cohort study comprising 87,879 patients with a first MI during the years when 73% of acute care hospitals in Sweden transitioned from cTn to hs-cTnT, the introduction of the hs-cTnT assay led to a decline in the annual incidence of MI, with no survival benefit, but with a reduced risk of reinfarction, alongside an increase in coronary angiographies and revascularizations. 
